Clinical Care Options: "Importance of Pharmacokinetics and Adherence to Avoid Emergence of Resistant HCV Variants"

A new CCO module is available here, focusing on the importance of PK and compliance to regimens in an effort to stem HCV resistance. The parallels between HCV antivirals and the evolution of HIV antiretrovirals are becoming numerous. Pharmacokinetics, pharmacogenetics and pharmacodynamics will all increase in importance as HCV drug development marketplace continues to move forward and potentially become as competitive as the HIV marketplace was back in the mid-90's and 2000's.

2012 Annual CCO HIV and Hepatitis C Symposium: Implementing Best Practices in HIV, HCV, and Coinfection

Register today for this weekend-long annual symposium covering the year’s most important new advances in the treatment of HIV and hepatitis C. Designed for frontline clinicians treating HIV- or HCV-monoinfected and/or coinfected patients, the highly interactive program features plenary presentations, interactive case discussions, and roundtable sessions reviewing the most up-to-date clinical information. Please check the Web site for the latest information on the confirmed agenda and faculty.

The Westin Diplomat
3555 South Ocean Drive
Hollywood, Florida

New CCO Module: Update of HCV Resistance from AASLD 2011

New Clinical Care Options CME Module now online: Update on HCV Resistance from AASLD 2011
Christoph Sarrazin, MD, reviews new data on resistance to direct-acting antiviral agents from the 2011 American Association for the Study of Liver Diseases conference. (Registration required)

Topics covered include:

New data on resistance to boceprevir and telaprevir
New data on resistance to second-wave and second-generation HCV protease inhibitors
Key findings on resistance to daclatasvir, an NS5A inhibitor
Current understanding of resistance to PSI-7977, a nucleotide polymerase inhibitor
New data on resistance to oral combination HCV therapies

Clinical Care Options inPractice now offering free online Hepatology textbook...

Clinical Care Options inPractice now offering free online Hepatology textbook....
CCO's inPractice now offering a new Hepatology medical textbook to complement their companion texts in Oncology and HIV. It's free and updated on a regular basis. It's search function allows you to browse for answers at the point of care. It can be found here: http://www.clinicaloptions.com/inPractice.aspx

Some of the texts include:

Virology and Immunology of Hepatitis Viruses
Hepatitis A and E
Hepatitis B Epidemiology, Pathogenesis, Diagnosis, and Natural History
Management of Hepatitis B Infection
Hepatitis B Management in Special Populations
Hepatitis Delta Virus
Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
Management of Hepatitis C Infection
Hepatitis C Management in Special Populations
Other Viruses That Affect the Liver

Clinical Care Options presents "Resistance in Hepatitis C"

A new CCO CME is online, this one taking a looks at Hepatitis C resistance in the era of the Direct Acting Anitivirals. Faculty includes Stephane Zeuzem MD, Stephane Chevaliez Pharm.D, Ph.D and Paul Pockros MD. Registration to CCO required.

Click here for the CME module

Clinical Care Options 2011 HIV & Hepatitis C Symposium...

2011 Annual CCO
HIV and Hepatitis C Symposium:

A Unique Program Integrating New Advances and Treatment Strategies in HIV, HCV, and Coinfection

June 9-12, 2011: Washington, DC

Mark your calendar today!

CCO has combined our 2 outstanding annual update symposia to provide a unique new meeting that addresses both the separate concerns of HCV and HIV treaters, as well as the intersection between these fields.

The program has been carefully structured to make it easy for participants to choose to attend the entire meeting or just the HIV or HCV sessions. Whether you treat only HIV, only HCV, or both, the flexibility of the program allows you to attend the sessions that are right for you.

A full day will address the latest issues in HIV management, including antiretroviral strategies, the management of comorbidities, and the emerging clinical role of pre-exposure prophylaxis.

Another full day of state-of-the-art educational content will address the clinical role of the new HCV agents that are expected to enter the clinic in 2011, including plenary reviews, roundtable discussions, and case-based learning.

Finally, a unique half-day session will explore the intersection between the epidemics, including management of coinfection, using the new HCV drugs in patients receiving antiretroviral therapy, and lessons the 2 fields are learning from each other.

Full Agenda and Online Registration Coming Soon

If you have any advance questions, please reply to this message or send an email to memberservices@clinicaloptions.com.